Abbott Laboratories Corporation

Jeffrey A Kester

Andrew Stewart Tasker

Steven Armen Boyd

Martin Winn

Thomas W Von Geldern

Charles W Hutchins

Bryan K Sorensen

Hwan-soo Jae

Gang Liu

Steven J Wittenberger

Steven A King

Bruce G Szczepankiewicz

Kenneth J Henry

Hwan-Soo Jae

Biswanath De

John F DeBernardis

Saul H Rosenberg

Anthony K Fung

Daniel Joseph Kerkman

Fatima Z Basha

Diane M Yamamoto

Thomas M Zydowsky

Kazumi Shiosaki

Robert J Padley

Todd J Janus

Thomas W Vongeldern

A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

Endothelin antagonists

A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, a method of antagonizing endothelin, methods for the inhibition of bone metastases, methods for the prevention of growth of new metastases, methods for the inhibition of bone turnover, and methods for the prevention of bone loss in patients, including cancer patients, using an endothelin ET-A receptor antagonist.

A compound of the formula (I):or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

Treatment of diseases using endothelin antagonists

A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

Compounds are disclosed having the formula: ##STR1## The compounds of the invention are angiotensin II receptor antagonists.

Angiotensin II receptor antagonists

Growing community of inventors

Deerfield, IL, United States of America

Jeffrey A Kester